keyword
MENU ▼
Read by QxMD icon Read
search

Melanoma cardiac

keyword
https://www.readbyqxmd.com/read/29792379/role-of-s-100%C3%AE-in-stroke
#1
Yongli He, Zhiyou Cai, Yangmei Chen
The S-100β levels are associated with a variety of acute disorders and other chronic diseases, such as head injury, stroke, metastatic melanoma, cardiac surgery, bone fractures, burns and contusions. The serum S-100β levels seem to increase with the volume of tissue damage. The higher serum S-100β levels have been observed after brain damage or stroke. A number of studies have evidenced the clinical value of S-100β in the diagnosis and prognosis of stroke while the S-100β marker is elevated in the peripheral blood during the acute phase of stroke...
May 24, 2018: International Journal of Neuroscience
https://www.readbyqxmd.com/read/29744020/cardiac-metastases-from-malignant-melanoma-the-charcoal-heart
#2
Herbert L Fred, Hendrik A van Dijk
The column in this issue is supplied by Herbert L. Fred, M.D., M.A.C.P., and Hendrik A. van Dijk, both from McGovern Medical School-UT Health, Houston, Texas. Dr. Fred is emeritus professor of medicine and a well-known medical educator and diagnostician. A graduate of Johns Hopkins University School of Medicine, he has authored just under 500 publications including six books. Mr. van Dijk, former director of the University of Texas Health Science Center Medical School's Graphic Communications Group, has devoted 50 years to biomedical communications and is a national expert in that field...
October 2017: Methodist DeBakey Cardiovascular Journal
https://www.readbyqxmd.com/read/29673080/systemic-sclerosis-and-malignancy
#3
Gokhan Sargin, Taskin Senturk, Songul Cildag
BACKGROUND: Systemic sclerosis (SSc) has increased risk of morbidity and mortality due to pulmonary fibrosis, pulmonary arterial hypertension, renal crisis, infections and malignancies. Chemical exposure, smoking and cytotoxic drugs increase the malignancy risk in rheumatic diseases including SSc. We aim to evaluate characteristics, identify risk factors and mortality in SSc patients with malignancies. METHODS: One hundred and fifty-three patients with SSc (24 male, 129 female, with mean age of 56...
April 19, 2018: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29604134/b4galnt2-and-xenotransplantation-a-newly-appreciated-xenogeneic-antigen
#4
REVIEW
Guerard Byrne, Saadullah Ahmad-Villiers, Zeji Du, Christopher McGregor
Analysis of non-Gal antibody induced after pig-to-baboon cardiac xenotransplantation identified the glycan produced by porcine beta-1,4-N-acetyl-galactosaminyltransferase 2 (B4GALNT2) as an immunogenic xenotransplantation antigen. The porcine B4GALNT2 enzyme is homologous to the human enzyme, which synthesizes the human SDa blood group antigen. Most humans produce low levels of anti-SDa IgM which polyagglutinates red blood cells from rare individuals with high levels of SDa expression. The SDa glycan is also present on GM2 gangliosides...
March 31, 2018: Xenotransplantation
https://www.readbyqxmd.com/read/29596556/uveal-melanoma-associated-with-myotonic-dystrophy-a-report-of-6-cases
#5
Lauren A Dalvin, Carol L Shields, Jose S Pulido, Kareem Sioufi, Victoria Cohen, Jerry A Shields
Importance: Patients with myotonic dystrophy (MD) have an increased risk of malignancy including uveal melanoma. This case series further explores the association between these 2 diseases. Objective: To describe a cohort of patients with uveal melanoma associated with MD, including a case of iris melanoma, and MD-associated uveal melanoma in relatives. Design, Setting, and Participants: Retrospective case series at 3 tertiary referral centers (Wills Eye Hospital, Philadelphia, Pennsylvania; Mayo Clinic, Rochester, Minnesota; and Moorsfields Eye Hospital, London, England), between January 1, 2000, and August 31, 2017...
March 29, 2018: JAMA Ophthalmology
https://www.readbyqxmd.com/read/29559799/upregulation-of-foxp1-is-a-new-independent-unfavorable-prognosticator-and-a-specific-predictor-of-lymphatic-dissemination-in-cutaneous-melanoma-patients
#6
Piotr Donizy, Konrad Pagacz, Jakub Marczuk, Wojciech Fendler, Adam Maciejczyk, Agnieszka Halon, Rafal Matkowski
Background: FOXP1 is a pleiotropic protein that plays important roles in immune responses (B-cell development regulation and differentiation of monocyte), organ development (cardiac valves, lung, and esophagus), and neuronal development. Besides being the primary regulator of normal human tissue development, FOXP1 also plays a role in tumorigenesis. However, the potential value of FOXP1 expression in tumor prognosis remains controversial. FOXP1 expression was assessed in tumor cells (TCs) and stromal cells (SCs) of cutaneous melanomas with the aim of analyzing the associations between FOXP1 expression and clinicopathological characteristics...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29512799/cardiac-metastases-4-cases-report
#7
Ines Ayedi, Hamed Chaabouni, Malek Akrout, Tahia Boudawara, Nabil Toumi, Afef Khanfir, Mounir Frikha
Cardiac metastases are rare. They are found in one to 10% of autopsies of patients withmalignant neoplasm. Adenocarcinoma represents the most common histologicaltype. The most common neoplasms that metastasize to the heart are lung andbreast cancers, melanoma, mesothelioma and lymphoma. However, Cardiacinvolvement is unusual in Hepatic, cutaneous and gastric cancer. We reportedthese three primary localizations in our cases.
June 2017: La Tunisie Médicale
https://www.readbyqxmd.com/read/29463229/metastatic-cardiac-tumors-from-clinical-presentation-through-diagnosis-to-treatment
#8
Ivana Burazor, Sarit Aviel-Ronen, Massimo Imazio, Orly Goitein, Marina Perelman, Natalia Shelestovich, Ninoslav Radovanovic, Vladimir Kanjuh, Iris Barshack, Yehuda Adler
BACKGROUND: To evaluate the prevalence of metastatic tumors involving the myocardium and study their presentation in order to increase awareness to their existence. METHODS: Pathological reports from Sheba Medical Center (Israel, January 1, 2010 through December 31, 2015) and medical records from The Institute for Cardiovascular Diseases of Vojvodina, Sremska Kamenica (Serbia, 23 years period) were screened for cases of metastatic cardiac tumors. Medical, radiological and pathological data of identified cases was retrieved and reviewed...
February 20, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29381409/complete-ophthalmoplegia-in-ipilmumab-and-nivolumab-combination-treatment-for-metastatic-melanoma
#9
Reem Alnabulsi, Ahsen Hussain, Dan DeAngelis
Ipilimumab and Nivolumab are novel monoclonal antibodies that have recently been used successfully for treatment of metastatic melanoma. Ipilimumab is a human monoclonal antibody against Cytotoxic T Lymphocyte Antigen 4 (CTLA4) receptor, which suppresses T-cell proliferation and stimulates an inflammatory response against cancer cells. Nivolumab is an IgG4 monoclonal antibody against the cytotoxic T lymphocyte associated programmed death 1 receptor (PD-1). Ipilimumab and Nivolumab combination treatment has been shown to induce remission and prolong survival in patients with metastatic melanoma...
January 30, 2018: Orbit
https://www.readbyqxmd.com/read/29215573/the-use-of-liposomes-and-nanoparticles-as-drug-delivery-systems-to-improve-cancer-treatment-in-dogs-and-cats
#10
REVIEW
Katarzyna Zabielska-Koczywąs, Roman Lechowski
BACKGROUND: Cancer remains a leading cause of death in companion animals. In human medicine, liposomes and nanoparticles have been extensively investigated as drug delivery systems (DDS) for anticancer agents due to their ability to target cancerous cells and reduce the negative side effects of free cytostatic drugs. In this review, the authors discuss the results of clinical trials using liposomes and polymer-based nanoparticles as DDS to improve cancer treatment in dogs and cats, indicating which ones seem worth further evaluation...
December 7, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29149136/mapk-pathway-targeted-therapies-care-and-management-of-unique-toxicities-in-patients-with-advanced-melanoma%C3%A2
#11
Krista M Rubin
BACKGROUND: Agents targeting the MAPK pathway, including inhibitors of BRAF and MEK, have dramatically transformed the treatment landscape for patients with BRAF-mutant metastatic melanoma. Although generally well tolerated, targeted agents were associated with unique toxicities.
. OBJECTIVES: This article aims to provide nurses with an overview of the key toxicities and associated management strategies of the characteristic adverse event (AE) profile associated with agents targeting the MAPK pathway...
December 1, 2017: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/29073846/the-incidence-of-non-melanoma-skin-cancer-and-post-transplant-lympho-proliferative-disorders-in-the-scottish-cardiac-transplant-population-and-the-provision-of-specialist-dermatological-follow-up
#12
Iain McPherson, Alan Kirk
Background Immunosuppression helps prevent acute rejection post-cardiac transplant but has been linked to malignancy development. This may be due to a reduction in T-lymphocyte function, a direct oncogenic effect or the increased impact of environmental carcinogens. There has been shown to be significant increases in non-melanoma skin cancers and post-transplant lympho-proliferative disorders, particularly in those treated with OKT3. Aim To investigate the survival and incidence of malignancy in the Scottish cardiac transplant population and whether rates of non-melanoma skin cancers justify the provision of specialist dermatological follow-up...
January 1, 2017: Scottish Medical Journal
https://www.readbyqxmd.com/read/28947426/self-reported-versus-health-administrative-data-implications-for-assessing-chronic-illness-burden-in-populations-a-cross-sectional-study
#13
Martin Fortin, Jeannie Haggerty, Steven Sanche, José Almirall
BACKGROUND: Various data sources may be used to document the presence of chronic medical conditions. This study examined the agreement between self-reported and health administrative data. METHODS: A randomly selected cohort of participants aged 25-75 years recruited by telephone from the general population of Quebec reported on the presence of 1 or more chronic conditions from a candidate list of 12 conditions: diabetes, hypertension, thyroid disorder, any cardiac disease, cancer diagnosis in the previous 5 years (including melanoma but excluding other skin cancers), asthma, osteoarthritis, rheumatoid arthritis or lupus, osteoporosis, chronic obstructive pulmonary disease, intestinal disease and hypercholesterolemia...
September 25, 2017: CMAJ Open
https://www.readbyqxmd.com/read/28923551/cardiac-melanoma-retrospective-review-of-a-rare-disease-at-the-mayo-clinic-1988-2015
#14
Chung Sang Tse, Nicholas Tan, Dame Idossa, Roger Click
BACKGROUND: Melanoma metastasizing to the heart (cardiac melanoma) is a rare entity that has been described only in autopsy studies or isolated pre-mortem case reports. We aim to better characterize cardiac melanoma, and describe its presenting features, imaging findings, and disease course with a case series collected over nearly 30years. METHODS: We performed a retrospective review of all patients diagnosed with cardiac melanoma at the Mayo Clinic from 1988 to 2015...
December 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28872489/a-case-of-pure-red-cell-aplasia-during-nivolumab-therapy-for-cardiac-metastatic-melanoma
#15
Akihiko Yuki, Tatsuya Takenouchi, Sumiko Takatsuka, Takuro Ishiguro
Nivolumab is an antibody against programmed cell death 1 and functions as an immune checkpoint inhibitor for various malignancies, including unresectable melanomas. Nivolumab causes several immune-related adverse events, which typically include skin rash, pneumonitis, thyroid dysfunction, hepatitis, and colitis; in rare cases, anemia may be present. There are several reports of autoimmune hemolytic anemia that has developed in response to nivolumab; however, there are few reports of pure red cell aplasia (PRCA)...
December 2017: Melanoma Research
https://www.readbyqxmd.com/read/28861837/cardiovascular-effects-of-the-mek-inhibitor-trametinib-a-case-report-literature-review-and-consideration-of-mechanism
#16
REVIEW
Mary Banks, Karen Crowell, Amber Proctor, Brian C Jensen
The MEK inhibitor trametinib was approved in 2013 for the treatment of unresectable or metastatic melanoma with a BRAF V600E mutation, the most common pathogenic mutation in melanoma. Trametinib blocks activation of ERK1/2, inhibiting cell proliferation in melanoma. ERK1/2 also protects against multiple types of cardiac insult in mouse models. Trametinib improves survival in melanoma patients, but evidence of unanticipated cardiotoxicity is emerging. Here we describe the case of a patient with metastatic melanoma who developed acute systolic heart failure after trametinib treatment and present the results of the literature review prompted by this case...
October 2017: Cardiovascular Toxicology
https://www.readbyqxmd.com/read/28853721/the-wide-spectrum-of-pot1-gene-variants-correlates-with-multiple-cancer-types
#17
Oriol Calvete, Pablo Garcia-Pavia, Fernando Domínguez, Gaelle Bougeard, Kristin Kunze, Andreas Braeuninger, Alex Teule, Adriana Lasa, Teresa Ramón Y Cajal, Gemma Llort, Victoria Fernández, Conxi Lázaro, Miguel Urioste, Javier Benitez
The POT1 protein binds and protects telomeres. Germline variants in the POT1 gene have recently been shown to be associated with risk of developing tumors in different tissues such as familial chronic lymphocytic leukemia, colorectal, glioma and melanoma tumors. Recently, we uncovered a variant in the POT1 gene (p.R117C) as causative of familial cardiac angiosarcomas (CAS) in Li-Fraumeni-like (LFL) syndrome families. Our in silico studies predicted that this protein had lost the ability to interact with TPP1 and single-stranded DNA...
November 2017: European Journal of Human Genetics: EJHG
https://www.readbyqxmd.com/read/28832802/occult-metastatic-melanoma-presenting-as-an-acute-coronary-syndrome
#18
Tiago R Velho, Nádia Junqueira, André Sena, Hugo Ferreira, Catarina Carvalheiro, Nuno Guerra, Javier Gallego, Ângelo Nobre
Melanoma is a tumor that virtually involves any tissue and commonly metastasizes to the heart. It is usually not diagnosed because of the absent/nonspecific cardiac signs and symptoms. Herein, we present a case of a 41-year-old man without any cardiovascular risk factor, admitted to the emergency room with chest pain, diagnosed with a myocardial infarction. Due to the presence of a mass adjacent to the mitral valve on the cardiac ultrasound examination, causing mitral regurgitation, the patient was referred to surgery...
May 2017: Brazilian Journal of Cardiovascular Surgery
https://www.readbyqxmd.com/read/28723725/meningeal-melanomatosis-following-discontinuation-of-dabrafenib-implications-for-the-maintenance-of-long-term-complete-remission
#19
Victoria Grätz, Nadine Lüttmann, Ozan Haase, Ewan A Langan, André Kemmling, Detlef Zillikens, Patrick Terheyden
A subset of 10-20% of patients under continuous BRAF inhibitor monotherapy achieve long-term progression-free and overall survival. Definitive criteria for the safe cessation of BRAF inhibitor monotherapy in treatment-responsive melanoma patients are lacking. We report a patient who remained in complete remission (CR) for 5 years under dabrafenib. The treatment was withdrawn because of concerns about cardiac toxicity. Four months thereafter the patient developed neurological symptoms, including diplopia and bilateral visual loss...
July 18, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28668146/a-rare-case-of-cardiac-melanoma-mimicking-hypertrophic-cardiomyopathy
#20
Imke Friedel, Wolfgang Burchert, Dieter Horstkotte, Lothar Faber
A 40-year-old female patient with a remote history of a malignant melanoma treated with curative intent presented with the diagnosis of hypertrophic cardiomyopathy (HCM) made at another hospital. Further diagnostic workup included positron emission tomography/computed tomography, which revealed that the HCM phenotype was produced by cardiac involvement of metastatic melanoma. For this reason, the primary diagnosis of HCM had to be retracted and melanoma-specific antineoplastic treatment was initiated.
July 2017: Canadian Journal of Cardiology
keyword
keyword
59279
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"